What is HC Wainwright’s Estimate for VNDA Q1 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Vanda Pharmaceuticals in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.03) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million during the quarter, compared to the consensus estimate of $59.28 million.

Other equities analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Finally, Jefferies Financial Group lifted their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $14.13.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $7.84 on Wednesday. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $9.60. The firm’s 50-day simple moving average is $7.53 and its two-hundred day simple moving average is $5.96. The stock has a market cap of $463.42 million, a PE ratio of -2.10 and a beta of 0.55. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth $25,000. Russell Investments Group Ltd. increased its holdings in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares in the last quarter. CWM LLC raised its position in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 7,575 shares during the last quarter. Quarry LP bought a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $53,000. Finally, Cerity Partners LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $69,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.